21 members of Congress sent a letter to the FDA regarding concerns about DSCSA implementation.
WASHINGTON — Yesterday, 21 members of Congress sent a letter to the FDA regarding concerns about DSCSA implementation. The letter urges the agency to take additional action to minimize the potential for disruptions in the drug supply chain and patient care as the November 27 implementation deadline looms. Numerous groups, including HDA, have voiced their concerns about the industry’s preparedness and called for a phased-in approach to implementation.
To read the full letter, click here.
Systemic changes like those in the PBM Reform Act must pass and be enacted as soon as possible. We’re grateful for this bill’s introduction and will do everything we can to push it across the finish line.”
The bill establishes powerful transparency requirements, bans spread pricing, assures fair reimbursement for pharmacies, and tackles anti-competitive practices that have driven up drug costs and limited patient choice.
White paper analyzes problems and solutions to patent abuses.
The program will be anchored by IPC’s iCare+ Independent Pharmacy Network, which includes thousands of community-rooted pharmacies nationwide and many in New Jersey.
Kantar’s David Marcotte noted that year-over-year continuity at the top underscores the market dominance of large-format retailers and vertically integrated omnichannel players.
The Journal reported that WK Kellogg shareholders will receive $23 per share in cash—representing a premium of roughly 40% over recent trading levels. Including debt, the transaction gives WK Kellogg a total enterprise value of about $3.1 billion.
Systemic changes like those in the PBM Reform Act must pass and be enacted as soon as possible. We’re grateful for this bill’s introduction and will do everything we can to push it across the finish line.”
The bill establishes powerful transparency requirements, bans spread pricing, assures fair reimbursement for pharmacies, and tackles anti-competitive practices that have driven up drug costs and limited patient choice.
